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Summary
1. Hospitals must have a major haemorrhage protocol in
place and this should include clinical, laboratory and
logistic responses.
2. Immediate control of obvious bleeding is of para-
mount importance (pressure, tourniquet, haemostatic
dressings).
3. The major haemorrhage protocol must be mobilised
immediately when a massive haemorrhage situation is
declared.
4. A ﬁbrinogen < 1 g.l
)1 or a prothrombin time (PT)
and activated partial thromboplastin time (aPTT) of
> 1.5 times normal represents established haemostatic
failure and is predictive of microvascular bleeding.
Early infusion of fresh frozen plasma (FFP;
15 ml.kg
)1) should be used to prevent this occurring
if a senior clinician anticipates a massive haemor-
rhage.
5. Established coagulopathy will require more than
15 ml.kg
)1 of FFP to correct. The most effective way
to achieve ﬁbrinogen replacement rapidly is by giving
ﬁbrinogen concentrate or cryoprecipitate if ﬁbrino-
gen is unavailable.
6. 1:1:1 red cell:FFP:platelet regimens, as used by the
military, are reserved for the most severely trauma-
tised patients.
7. A minimum target platelet count of 75 · 10
9.l
)1 is
appropriate in this clinical situation.
8. Group-speciﬁc blood can be issued without perform-
ing an antibody screen because patients will have
minimal circulating antibodies. O negative blood
should only be used if blood is needed immediately.
9. In hospitals where the need to treat massive
haemorrhage is frequent, the use of locally developed
shock packs may be helpful.
10. Standard venous thromboprophylaxis should be
commenced as soon as possible after haemostasis has
been secured as patients develop a prothrombotic
state following massive haemorrhage.
Introduction
There are an increasing number of severely injured
patients who present to hospital each year. Trauma is the
leading cause of death in all ages from 1 to 44 years.
Haemorrhagic shock accounts for 80% of deaths in the
operating theatre and up to 50% of deaths in the ﬁrst 24 h
after injury. Only 16% of major emergency departments
in the UK use a massive haemorrhage guideline [1].
The management of massive haemorrhage is usually
only one component of the management of a criti-
cally unwell patient. These guidelines are intended to
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speciﬁcally directed at improving management of massive
haemorrhage [2]. The guidance is intended to provide a
better understanding of the priorities in speciﬁc situations.
Effective teamwork and communication are an essential
part of this process.
Deﬁnitions of massive haemorrhage vary and have
limited value. The Working Party suggests that the
nature of the injury will usually alert the anaesthetist to
the probability of massive haemorrhage and can be
arbitrarily considered as a situation where 1–1.5 blood
volumes may need to be infused either acutely or within
a 24-h period.
The formulation of guidance in the style of previous
AAGBI guidelines has been difﬁcult in such a rapidly
changing area. The grade of evidence has not been
mentioned within the text, but the editing of the ﬁnal
draft and Working Party membership have been
cross-checked with other recently published documents.
The Working Party believes that at the current time,
its advice is consistent with recently published
European guidelines and the availability of current
evidence [3–5].
It is envisaged that the website version of this
document will be updated at least annually and earlier if
an addendum or correction is deemed urgent.
Organisational aspects
Hospitals must have a major haemorrhage protocol in
place and this should include clinical, laboratory and
logistic responses. Protocols should be adapted to spe-
ciﬁc clinical areas. It is essential to develop an effective
method of triggering the appropriate major haemorrhage
protocol.
Roles within a team
Team leader
The team leader is the person who declares a massive
haemorrhage situation; this is usually the consultant or the
most senior doctor at the scene. Their role is to direct and
co-ordinate the management of the patient with massive
haemorrhage.
Communication
The team leader should appoint a member of the team as
communications lead whose sole role is to communicate
with the laboratories and other departments.
Collection of blood samples, blood and components
A member of the team should be allocated to convey
blood samples, blood and blood components between the
laboratory and the clinical area. This role is usually taken
by a porter or healthcare support worker who should
ideally be in constant radio communication with the
team. In their absence, a nurse or doctor should be
identiﬁed to take on this role.
Securing intravenous and central access
A member of the team should be identiﬁed whose role is
to secure intravenous access, either peripherally or
centrally. Large-bore 8-Fr. central access is the ideal in
adults; in the event of failure, intra-osseous or surgical
venous access may be required.
Switchboard
The switchboard must alert certain key clinical and
support people when a massive haemorrhage situation is
declared. These include
• Hospital Transfusion Laboratory Biomedical Scientist
(BMS) or equivalent
• Coagulation Biomedical Scientist (BMS) or equivalent
• Haematologist on call
• ICU senior doctor on site
• ICU Nurse in charge
• Surgical senior doctor on site
• Radiologist on call
Dealing with the patient with massive
haemorrhage
There are both clinical and logistic issues to consider.
These include clinical management of the patient, setting
processes in place to deliver blood and blood components
to the patient, and organisation of emergency interven-
tions to stop the bleeding (surgical or radiological). There
are two common scenarios:
A massively bleeding ⁄injured ⁄ill patient en route
With warning, resources and personnel can be mobilised
to be in position to receive the patient. A brief history can
alert the team to the risk of massive bleeding:
• History of trauma (blunt or penetrating)
• Obstetric patient
• Major surgery (neurosurgery, spinal, cardiac, liver
surgery)
• Underlying medical condition affecting coagulation
Presentation of a patient with minimal or no notice
This is the common scenario in the accident and
emergency department. Here, the immediate concern is
hands-on management of the patient:
• Stop any external bleeding
• Assess the patient and treat
• Trigger massive haemorrhage protocol
• Move to the next appropriate level of care
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massive haemorrhage
• Control obvious bleeding points (pressure, tourniquet,
haemostatic dressings)
• Administer high FIO2
• IV access – largest bore possible including central access
• If patient is conscious and talking and a peripheral pulse
is present, the blood pressure is adequate.
• Baseline bloods – full blood count (FBC), prothrombin
time (PT), activated partial thomboplastin time (aPTT),
Clauss ﬁbrinogen* and cross-match.
• If available, undertake near-patient testing e.g.
thromboelastography (TEG) or thromboelastometry
(ROTEM).
• Fluid resuscitation – in the massive haemorrhage
patient, this means warmed blood and blood compo-
nents. In terms of time of availability, blood group O is
the quickest, followed by group speciﬁc, then cross-
matched blood.
• Actively warm the patient and all transfused ﬂuids.
• Next steps: rapid access to imaging (ultrasound,
radiography, CT), appropriate use of focused assess-
ment with sonography for trauma scanning and ⁄or
early whole body CT if the patient is sufﬁciently stable,
or surgery and further component therapy.
• Alert theatre team about the need for cell salvage
autotransfusion.
*A derived ﬁbrinogen is likely to be misleading and should not be
used.
Ongoing assessment
• Look at injury patterns
• Look for obvious blood loss (on clothes, on the ﬂoor,
in drains)
• Look for indications of internal blood loss
• Assess physiology (skin colour, heart rate, blood
pressure, capillary reﬁll, conscious level)
Some patients compensate well despite signiﬁcant blood
loss. A rapid clinical assessment will give very strong
indications of those at risk. It is important to restore organ
perfusion, but it is not necessary to achieve a normal
blood pressure at this stage [6–8].
Further management
Once control of bleeding is achieved, aggressive attempts
should be made to normalise blood pressure, acid-base
status and temperature, but vasopressors should be
avoided. Active warming is required. Coagulopathy
should be anticipated and, if possible, prevented. If
present, it should be treated aggressively (see Dealing with
coagulation problems).
Surgery must be considered early. However, surgery
may have to be interrupted and limited to ‘damage
control’. Once bleeding has been controlled, abnormal
physiology can be corrected [9–11].
Following treatment for massive haemorrhage, the
patient should be admitted to a critical care area for
monitoring and observation, and monitoring of coagula-
tion, haemoglobin and blood gases, together with wound
drain assessment to identify overt or covert bleeding.
Venous thromboprophylaxis
Standard venous thromboprophylaxis should be com-
menced as soon as possible after bleeding has been con-
trolled, as patients rapidly develop a prothrombotic state.
Temporary inferior vena cava ﬁltration may be necessary.
Dealing with coagulation problems
Haemostatic defects in massive haemorrhage
The haemostatic defect in massive haemorrhage will vary,
depending on the amount and cause of bleeding and
underlying patient-related factors. It is likely to evolve
rapidly. Patient management should be guided by labo-
ratory results and near-patient testing, but led by the
clinical scenario.
Dilutional coagulopathy
All patients being treated for massive haemorrhage are at
risk of dilutional coagulopathy leading to reduced plate-
lets, ﬁbrinogen and other coagulation factors. This occurs
if volume replacement is with red cells, crystalloid and
plasma expanders, and insufﬁcient infusion of fresh frozen
plasma (FFP) and platelets. Dilutional coagulopathy
should be prevented by early infusion of FFP.
Consumptive coagulopathy
Some patients with massive haemorrhage are also at risk
of a consumptive coagulopathy and are liable to develop
haemostatic failure without signiﬁcant dilution. Con-
sumption is commonly seen in obstetric haemorrhage,
particularly associated with placental abruption and
amniotic ﬂuid embolus, in patients on cardiopulmonary
bypass (CPB), following massive trauma especially
involving head injury, and in the context of sepsis.
Activation of anticoagulant pathways is associated with
massive trauma and patients may have haemostatic
compromise without abnormal coagulation tests [12].
Platelet dysfunction is associated with CPB, renal disease
and anti-platelet medication.
Hyperﬁbrinolysis is particularly associated with obstetric
haemorrhage, CPB and liver surgery.
Anticoagulant drugs
In the context of massive haemorrhage, warfarin should
be reversed with a prothrombin complex concentrate
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dependent on the international normalised ratio (INR)
(see Table 1).
Unfractionated heparin can be reversed with protamine
(1 mg protamine reverses 100 u heparin). Excess prot-
amine induces a coagulopathy. Usual reversal is by
infusing either 25 or 50 mg of intravenous protamine.
Low molecular weight heparin can be partially reversed
with protamine.
Direct thrombin and factor Xa inhibitors e.g. fondaparinux,
dabigatran and rivaroxaban cannot be reversed.
Aspirin and P2Y12 antagonists
Patients taking aspirin have a low risk of increased
bleeding, whilst those on P2Y12 antagonists have a higher
risk. The anti-platelet effect of aspirin can be reversed by
platelet transfusion, but the effect of the P2Y12 antago-
nist, clopidogrel, is only partially reversed by platelets.
Inherited bleeding disorders
It is very likely that patients with an inherited bleeding
disorder will be registered with a haemophilia centre and
urgent advice should be sought if they present with
massive haemorrhage.
Liver disease
Liver disease is associated with decreased production of
coagulation factors, natural anticoagulants and the
production of dysfunctional ﬁbrinogen (dysﬁbrinogen-
aemia). It should be anticipated that these patients will
develop a clinically signiﬁcant dilutional coagulopathy
and haemostatic failure with bleeds less than one blood
volume.
Interpretation of laboratory tests
A ﬁbrinogen < 1 g.l
)1 or a PT and aPTT > 1.5 times
normal represents an established haemostatic failure and is
predictive of microvascular bleeding. Early infusion of
FFP should be used to prevent this occurring if a senior
clinician anticipates a massive haemorrhage.
Clauss ﬁbrinogen is an easily available test and should be
speciﬁcally requested if not part of the routine coagulation
screen. The ﬁbrinogen level is more sensitive than the PT
and aPTT to a developing dilutional or consumptive
coagulopathy. Levels below 1 g.l
)1, in the context of
massive haemorrhage, are usually insufﬁcient, and emerg-
ing evidence suggests that a level above 1.5 g.l
)1 is
required. Higher levels are likely to improve haemostasis
further.
A platelet count below 50 · 10
9.l
)1 is strongly associated
with haemostatic compromise and microvascular bleeding
in a patient being treated for massive haemorrhage. A
minimum target platelet count of 75 · 10
9.l
)1 is appro-
priate in this clinical situation.
The PT is an insensitive test for haemostatic compro-
mise and a relatively normal result should not necessarily
reassure the clinician. It is common practice to correct to
PT to within 1.5 of normal; however, this may not be an
appropriate target in many situations [13].
An INR is not an appropriate test in massive haemor-
rhage because it is standardised for warfarin control, and
results may be misleading in the context of dilutional and
consumptive coagulopathies and liver disease.
The aPTT is commonly used to guide blood product
replacement but, as with the PT, correcting to 1.5 times
normal is not necessarily an appropriate strategy because
haemostatic failure may already be signiﬁcant at this level.
The aPTT should be maintained below 1.5 times normal
as the minimum target.
If whole blood point of care testing is used, a protocol
for blood product usage based on thromboelastogram
(TEG ⁄ROTEM) results should be agreed in advance.
Haemostatic tests and FBC should be repeated at least
every hour if bleeding is ongoing, so that trends may be
observed and adequacy of replacement therapy docu-
mented. Widespread microvascular oozing is a clinical
marker of haemostatic failure irrespective of blood tests
and should be treated aggressively.
Management of haemostasis
The coagulopathy during massive haemorrhage is likely
to evolve rapidly and regular clinical review and blood
tests are required. It is important to anticipate and prevent
haemostatic failure, but if haemostatic failure has
occurred, standard regimens (e.g. FFP 15 ml.kg
)1) can
be predicted to be inadequate and larger volumes of FFP
are likely to be required.
Prevention of coagulopathy
Emerging evidence supports the early use of FFP to
prevent dilutional coagulopathy. If an experienced
clinician anticipates a blood loss of one blood volume,
FFP should be infused to prevent coagulopathy. While
FFP 15 ml.kg
)1 is appropriate for uncomplicated cases,
increased volumes of FFP will be needed if a consumptive
Table 1 Possible regimen for prothrombin complex concentrate
(PCC).
INR Dose of PCC; u.kg
)1
2–3.9 25
4–5.9 35
>6 5 0
INR, international normalised ratio.
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disease.
A minimum target platelet count of 75 · 10
9.l
)1 is
appropriate in this clinical situation.
1:1:1 red cell:FFP:platelet regimens, as used by the
military, are reserved for the most severely traumatised
patient and are not routinely recommended [14, 15].
Treatment of haemostatic failure
In the context of massive haemorrhage, patients with
widespread microvascular oozing or with coagulation
tests that demonstrate inadequate haemostasis (ﬁbrinogen
< 1 g.l
)1 or PT ⁄aPTT > 1.5 above normal), should be
given FFP in doses likely to correct the coagulation factor
deﬁciencies. This will require more than 15 ml.kg
)1, and
at least 30 ml.kg
)1 would be a reasonable ﬁrst-line
response [16, 17].
Platelets should be maintained at at least 75 · 10
9.l
)1
[2, 18].
Although it is often recommended that hypoﬁbrino-
genaemia unresponsive to FFP be treated with cryopre-
cipitate, treatment may be associated with delays because
of thawing and transportation.
Fibrinogen replacement can be achieved much more
rapidly and predictably with ﬁbrinogen concentrate (no
requirement for thawing as for cryoprecipitate) given at a
dose of 30–60 mg.kg
)1. This product is not currently
licensed in the UK and must be given on a named patient
basis. Fibrinogen concentrate is licensed in many Euro-
pean countries to treat both congenital and acquired
hypoﬁbrinogenaemia [19].
Hyperﬁbrinolysis
Intravenous tranexamic acid should be used in clinical
situations where increased ﬁbrinolysis can be anticipated.
Support for its use has strengthened recently with the
positive report of its use in traumatic haemorrhage [20]
(see Other interventions on pharmacological manage-
ment of massive haemorrhage).
Hypocalcaemia and hypomagnesaemia are often asso-
ciated with massively transfused patients and will need
monitoring and correction.
rFVIIa
This drug has been used for treatment of massive
haemorrhage unresponsive to conventional therapy.
Recent review of data has highlighted the risk of arterial
thrombotic complications and the speciﬁcation of prod-
uct characteristics now states: ‘Safety and efﬁcacy of
NovoSeven (rFVIIa) have not been established outside
the approved indications and therefore NovoSeven
should not be used’. Where centres decide to use this
therapy, local protocols must be agreed in advance.
rFVIIa is usually given with tranexamic acid and is not as
efﬁcacious if the patient has a low ﬁbrinogen.
Some centres use PCC (concentrated factors II, VII, IX
and X) in certain clinical situations such as liver disease
and post-CPB; local protocols must be agreed in advance.
Logistics of blood supply
Identiﬁcation
Positive patient identiﬁcation is essential at all stages of the
blood transfusion process and a patient should have two
identiﬁcation bands in situ. The healthcare professional
administering the blood component must perform the
ﬁnal administrative check for every component given. All
persons involved in the administration of blood must be
trained and certiﬁcated in accordance with national
standards.
Standard issue
Pre-transfusion procedures are designed to determine the
patient’s ABO and Rhesus D (RhD) status, to detect red
cell antibodies that could haemolyse transfused cells and
conﬁrm compatibility with each of the units of red cells to
be transfused. Red cell selection may be based on a
serological cross-match or electronic issue. Standard issue
of red cells may take approximately 45 min.
Emergency issue
Group O RhD negative is the blood group of choice for
transfusion of red cells in an emergency where the clinical
need is immediate. However, overdependence on group
O RhD negative red cells may have an adverse impact on
local and national blood stock management and it is
considered acceptable to give O RhD positive red cells to
male patients.
Hospitals should avoid the need for elective transfusion
of group O RhD negative red cells to non-O RhD
negative recipients. Clinical staff should endeavour to
provide immediate blood samples for grouping in order to
allow the use of group speciﬁc blood.
In the emergency situation, blood can be issued
following identiﬁcation of group without knowing the
result of an antibody screen – ‘group speciﬁc blood’.
Grouping can be performed in about 10 min, not
including transfer time, and group speciﬁc blood can be
issued. This of course is a higher risk strategy and depends
on the urgency for blood. In massive bleeding, patients
will have minimal circulating antibodies, so will usually
accept group speciﬁc blood without reaction. If the
patient survives, antibodies may develop at a later stage.
Women who are RhD negative and of childbearing
age, who are resuscitated with Rh D positive blood or
platelets, can develop immune anti-D, which can cause
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nancies. To prevent this, a combination of exchange
transfusion and anti-D can be administered, on the advice
of a haematologist, within 72 h of the transfusion.
Blood storage and transfer
Cold chain requirements are essential under European
Law. Blood should be transfused within 4 h of leaving a
controlled environment. Blood issued cannot be returned
to stock if out of a controlled temperature and monitored
fridge for longer than 30 min. If blood is issued within a
correctly packed and validated transport box, the blood
should be placed back in a blood fridge normally within
2 h, providing the box is unopened. Blood transfusion
laboratory staff will then assess the acceptability of blood
for return to stock. Only in exceptional circumstances
should blood components be transferred with a patient
between hospital trusts or health boards.
Traceability
It is a statutory requirement that the fate of all blood
components must be accounted for. These records must
be held for 30 years. Staff must be familiar with local
protocols for recording blood use in clinical notes and for
informing the hospital transfusion laboratory.
The hospital transfusion committee is the ideal forum to
allow cross-specialty discussions about protocols and
organisation for dealing with massive haemorrhage. Audit
of previous instances allows a reﬁnement of response to
ensure efﬁcient and timely treatment. This level of
organisation can only be arranged at a local level.
Stock management of labile components when there is
unpredictable demand is a challenge. Large stock-holding
is associated with wastage, whereas insufﬁcient stocks may
lead to clinical disaster.
Most hospitals rely on rapid re-supply of platelets from
the Blood Service rather than holding stocks. Anaesthe-
tists need to be aware of local arrangements and the
normal time interval for obtaining platelets in an emer-
gency.
Blood shortages
National demand for blood components may exceed
supply. National blood shortage plans will be activated in
the event of red cell and platelet shortages. Guidance is
given for the prioritisation of patient groups during
shortage. The transfusion support during massive haem-
orrhage is a priority. However, it is expected that all
efforts be made to stop the bleeding and reduce the need
for donor blood. The use of cell salvage is encouraged in
all cases of massive haemorrhage (Further information is
available in Blood Transfusion and the Anaesthetist – Intra-
operative Cell Salvage. AAGBI: http://www.aagbi.
org/publications/guidelines/docs/cell%20_salvage_2009_
amended.pdf).
Blood components
This section advises on the appropriate use of blood
components during massive haemorrhage (see Dealing
with coagulation problems). This advice is required
because red cell concentrates do not contain coagulation
factors or platelets.
Patients with massive haemorrhage may require all
blood components. Blood may be required not just at the
time of resuscitation, but also during initial and repeat
surgery. The beneﬁts of timely and appropriate transfu-
sion support in this situation outweigh the potential risks
of transfusion and may reduce total exposure to blood
components.
(Further information is available in Blood Transfusion
and the Anaesthetist – Blood Component Therapy. AAGBI:
http://www.aagbi.org/publications/guidelines/docs/
bloodtransfusion06.pdf).
Paediatric components
A comprehensive guideline for neonatal and paediatric
transfusion together with a recent update statement is
available at http://www.bcshguidelines.com/. Useful
principles are: minimise and stop blood loss; minimise
donor exposure; and use paediatric components where
readily available (See Table 2).
Equipment to aid transfusion
Giving sets, ﬁlters and pressure infusion
All blood components should be administered using a
blood component administration set, which incorporates
a 170–200 lm ﬁlter.
There is no current need to use any sort of additional
ﬁlter in massive haemorrhage when using allogeneic
Table 2 Blood component volumes and rates of administration
for infants and children.
Component Volume
Red cell
concentrates
Vol (ml) = desired Hb rise (g.dl
)1) · wt (kg) · 3
Platelets Children < 15 kg (10–20 ml.kg
)1)
Children > 15 kg (1 adult bag)
FFP (MB treated) 10–20 ml.kg
)1
Cryoprecipitate 5–10 ml.kg
)1 (usually max 10 units – approx
300 ml)
Vol, volume; Hb, haemoglobin; FFP, fresh frozen plasma; MB,
methylene blue.
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process unnecessary. If red cell salvage is being used, a
40-lm ﬁlter may still be indicated e.g. if small bone
fragments contaminate the surgical ﬁeld.
Although a special platelet giving set is ideally used
for platelet transfusion, it is unnecessary in massive
haemorrhage. The important issue is to administer
platelets via a clean 170–200 lm giving set (see below),
as one that has previously been used for red cells may
cause the platelets to stick to the red cells and therefore
reduce the effective transfused platelet dose.
The use of an adequate warming device is recom-
mended in massively bleeding patients and this equipment
needs to be available in all emergency rooms and theatre
suites, allowing adequate warming of administered blood
at high infusion rates.
Infusion devices
• Only blood component administration sets that are
compatible with the infusion device should be used
(check manufacturers’ recommendations). Infusion
devices should be regularly maintained and any adverse
outcome as a result of using an infusion device to
transfuse red cells should be reported to the Medical
Devices section of the Medicines and Healthcare
products Regulatory Agency (MHRA).
• Administration sets used with infusion devices should
incorporate an integral mesh ﬁlter (170–200 lm).
• The pre-administration checking procedure should
include a check of the device and device settings.
Infusion rate devices
• Either gravity or electronic infusion devices may be
used for the administration of blood and blood
components. Infusion devices allow a precise infusion
rate to be speciﬁed.
• Rapid infusion devices may be used when large
volumes have to be infused quickly, as in massive
haemorrhage. These typically have a range of 6–
30 l.h
)1 and usually incorporate a blood-warming
device.
• Infusion devices should only be used if the manufac-
turer veriﬁes them as safe for this purpose and they are
CE-marked.
• The volume delivered should be monitored regularly
throughout the infusion to ensure that the expected
volume is delivered at the required rate.
Pressure devices
• External pressure devices make it possible to administer
a unit of red cells within a few minutes. They should
only be used in an emergency situation together with a
large-gauge venous access cannula or device.
• External pressure devices should:
• Exert pressure evenly over the entire bag;
• Have a gauge to measure the pressure;
• Not exceed 300 mmHg of pressure;
• Be monitored at all times when in use.
Blood warmers
• In all adults undergoing elective or emergency
surgery (including surgery for trauma) under general
or regional anaesthesia, ‘intravenous ﬂuids (500 ml or
more) and blood components should be warmed to
37  C’ [21, 22]. The greatest beneﬁt is from the
controlled warming of red cells (stored at 4  C)
rather than platelets (stored at 22 ± 2  C) or FFP ⁄
cryoprecipitate (thawed to 37  C) [23]. Of note,
there is no evidence to suggest that infusion
of platelets or FFP through a blood warmer is
harmful.
• In most other clinical situations where there is concern,
it is sufﬁcient to allow blood to rise to ambient
temperature before transfusion. Special consideration
should be given when rapidly transfusing large volumes
to neonates, children, elderly patients and patients
susceptible to cardiac dysfunction.
• Blood should only be warmed using approved, specif-
ically designed and regularly maintained blood warm-
ing equipment with a visible thermometer and audible
warning. Settings should be monitored regularly
throughout the transfusion.
• Blood components should never be warmed using
improvisations, such as putting the pack in warm water,
in a microwave or on a radiator.
Other interventions
Pharmacological management options
Antiﬁbrinolytics
Fibrinolysis is the process whereby established ﬁbrin clot
is broken down. This can occur in an accelerated fashion,
destabilising effective coagulation in many clinical situa-
tions associated with massive haemorrhage, including
multiple trauma, obstetric haemorrhage and major organ
surgery (e.g. cardiothoracic, liver) including transplanta-
tion surgery.
Accelerated ﬁbrinolysis can be identiﬁed by labora-
tory assay of d-dimers or ﬁbrin degradation products, or
by use of coagulation monitors such as TEG or
ROTEM. It is accepted that not all hospitals can
provide either the hardware or expertise to interpret
TEG and ROTEM.
Antiﬁbrinolytic drugs, such as tranexamic acid, have
been used to reverse established ﬁbrinolysis in the setting
of massive blood transfusion.
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from randomised controlled trials to support the routine
use of antiﬁbrinolytic agents in managing massive haem-
orrhage, they are considered effective if accelerated
ﬁbrinolysis is identiﬁed.
Tranexamic acid inhibits plasminogen activation, and at
high concentration inhibits plasmin. The recent CRASH-
2 trial supports its use at a loading dose of 1 g over 10 min
followed by 1 g over 8 h [20]. There are few adverse
events or side effects associated with tranexamic acid use in
the setting of massive haemorrhage [20]. Repeat doses
should be used with caution in patients with renal impair-
ment, as the drug is predominantly excreted unchanged by
the kidneys. It is contraindicated in patients with sub-
arachnoid haemorrhage, as anecdotal experience suggests
that cerebral oedema and cerebral infarction may occur.
Aprotinin is a serine protease inhibitor, inhibiting
trypsin, chymotrypsin, plasmin and kallikrein. It has been
used to reduce blood loss associated with accelerated
ﬁbrinolysis in major surgery (e.g. cardiothoracic surgery,
liver transplantation). Recently, there have been concerns
about the safety of aprotinin. Anaphylaxis occurs at a rate
of 1:200 in ﬁrst-time use. A study performed in cardiac
surgery patients reported in 2006 showed that there was
indeed a risk of acute renal failure, myocardial infarction
and heart failure, as well as stroke and encephalopathy
[24]. As a result of this, and other follow-up work, the
MHRA recommends that aprotinin should only be used
when the likely beneﬁts outweigh any risks to individual
patients. As a result, use of aprotinin is now limited to
highly specialised surgical situations, e.g. cardiac and liver
transplantation, and is used on a named patient basis only.
Factor concentrates
Coagulation factor concentrates may be required for
patients with inherited bleeding disorders such as hae-
mophilia or von Willebrand disease. They should only
be used under the guidance of a haemophilia centre. (For
recombinant factor VIIa, prothrombin complex concen-
trate and ﬁbrinogen concentrate, see Dealing with
coagulation problems).
Non-pharmacological management options
Radiologically aided arterial embolisation
These techniques are becoming more widespread and
successful cessation of bleeding can be achieved with
embolisation of bleeding arteries following angiographic
imaging. The suitability of such manoeuvres needs to be
assessed in each individual case and will also depend on
availability of an interventional radiologist. The technique
can be remarkably effective and may eliminate the need
for surgical intervention, particularly in major obstetric
haemorrhage.
Cell salvage
The use of intra-operative cell salvage can be very
effective at both reducing demand on allogeneic supplies
and providing a readily available red cell supply in massive
haemorrhage. National Institute of Health and Clinical
Excellence (NICE) guidelines have also supported its use
where large blood loss is experienced in obstetric
haemorrhage and complex urological surgery such as
radical prostatectomy. The indications for cell salvage
are detailed in Blood Transfusion and the Anaesthetist –
Intra-operative Cell Salvage (http://www.aagbi.org/
publications/guidelines/docs/cell%20_salvage_2009_
amended.pdf).
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